Lipid-lowering APOB variants were associated with a decreased risk of thyroid cancer (OR 0.52; 95% CI: 0.36 to 0.75; p-IVW=4.29×10-4, FDR=2.81×10-3). Here, APOB is linked to thyroid cancer.